Show simple item record

dc.contributor.authorCross, Alan S
dc.contributor.authorOpal, Steven M
dc.contributor.authorPalardy, John E
dc.contributor.authorShridhar, Surekha
dc.contributor.authorBaliban, Scott M
dc.contributor.authorScott, Alison J
dc.contributor.authorChahin, Abdullah B
dc.contributor.authorErnst, Robert K
dc.date.accessioned2021-04-29T17:50:52Z
dc.date.available2021-04-29T17:50:52Z
dc.date.issued2021-04-16
dc.identifier.urihttp://hdl.handle.net/10713/15542
dc.description.abstractDespite the dramatic increase in antimicrobial resistance, there is a dearth of antibiotics in development and few pharmaceutical companies working in the field. Further, any new antibiotics are likely to have a short shelf life. Ab-based interventions offer alternatives that are not likely to be circumvented by the widely prevalent antibiotic resistance genes. Bovine colostrum (BC)-the first milk after parturition, rich in nutrients and immune components-promotes gut integrity and modulates the gut microbiome. We developed a hyperimmune BC (HBC) enriched in Abs to a highly conserved LOS core region of Gram-negative bacteria by immunizing pregnant cows with a vaccine comprised of detoxified LOS from Escherichia coli O111 Rc (J5) mutant non-covalently complexed to group B meningococcal outer membrane protein (J5dLOS/OMP). This vaccine generated robust levels of anti-J5 LOS Ab in the colostrum. When given orally to neutropenic rats challenged orally with Pseudomonas aeruginosa, administration of HBC improved survival compared to non-immune rats, while both BC preparations improved survival compared to PBS controls. Elevated circulating endotoxin levels correlated with mortality. HBC and to a lesser extent non-immune BC reduced bacterial burden from the liver, lung, and spleen. We conclude that HBC and to a lesser extent BC may be effective supplements that improve outcome from lethal gut-derived disseminated infection and may reduce transmission of Gram-negative bacilli from the gastrointestinal tract.en_US
dc.description.urihttps://doi.org/10.1177/17534259211007538en_US
dc.language.isoenen_US
dc.publisherSAGE Publications Inc.en_US
dc.relation.ispartofInnate Immunityen_US
dc.subjectAntibodyen_US
dc.subjectPseudomonas aeruginosaen_US
dc.subjectantimicrobial resistanceen_US
dc.subjectbovine colostrumen_US
dc.subjectendotoxinen_US
dc.titleA pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsisen_US
dc.typeArticleen_US
dc.identifier.doi10.1177/17534259211007538
dc.identifier.pmid33858243
dc.source.volume27
dc.source.issue3
dc.source.beginpage266
dc.source.endpage274
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record